-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GDQKky0HrwJgjSYHbWCiZC5osJ6R07X7alghR1UYT56H9MekCuElxqYFY46eZIZN
 KlyzLuzfX2Pa4u5BjfTFiA==

<SEC-DOCUMENT>0001144204-10-041164.txt : 20100804
<SEC-HEADER>0001144204-10-041164.hdr.sgml : 20100804
<ACCEPTANCE-DATETIME>20100804155908
ACCESSION NUMBER:		0001144204-10-041164
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100804
FILED AS OF DATE:		20100804
DATE AS OF CHANGE:		20100804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		10991002

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v192466_6k.htm
<TEXT>
<html>
  <head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.1-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
the Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
month of August, 2010</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number: <font style="DISPLAY: inline; FONT-WEIGHT: bold">000-51310</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: none">XTL Biopharmaceuticals
Ltd.</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div>
      <hr style="COLOR: black" align="center" noshade size="1" width="40%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Kiryat
Weizmann Science Park</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3
Hasapir Street, Building 3, PO Box 370</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: none">Rehovot 76100,
Israel</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: black" align="center" noshade size="1" width="40%">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;(Address
of principal executive offices)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 20-F
<font style="DISPLAY: inline;" face="Wingdings">x</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Form 40-F <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes <font style="DISPLAY: inline;" face="Wingdings">o</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;N/A</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font id="TAB1" style="MARGIN-LEFT: 432pt"></font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated August 4, 2010
is hereby incorporated by reference into the registration statements on Form F-3
(File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL
Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23,
2007 , October 30, 2007 and August 15, 2008, respectively, and the registration
statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No.
333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and
Exchange Commission on December 14, 2007, January 18, 2008, and October 28,
2008, respectively.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
Biopharmaceuticals Announces</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Completion
of the Bio-Gal Transaction</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attached&#160;hereto
is an English translation (from Hebrew) of today&#8217;s announcement of the
completion of the Bio-Gal transaction, as submitted on Tel Aviv Stock
Exchange.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 2
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><img src="logo.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">XTL Biopharmaceuticals,
Ltd.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(the
&#8220;Company&#8221;)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">August 4,
2010</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div align="left">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="70%">
          <tr>
            <td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To:</font></td>
            <td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To:</font></td>
          </tr>
          <tr>
            <td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">Israel
      Securities Authority</font></td>
            <td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">Tel-Aviv
      Stock Exchange, Ltd.</font></td>
          </tr>
          <tr>
            <td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(via
MAGNA)</font></td>
            <td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(via
  MAGNA)</font></td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To whom
it may concern,</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject:
<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Completion
of XTL-Xtepo (Bio-Gal) Transaction</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the report published by the Company on January 15, 2010 (ref. 2010-01-355722)
and on March 2, 2010 (ref. 2010-01-400827) in connection with the Company&#8217;s
engagement in a share transfer agreement with Xtepo, Ltd. (the &#8220;Share Transfer
Agreement&#8221;, and &#8220;Xtepo&#8221;, respectively), <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">the
Company hereby announces that the transaction has been completed on August 3,
2010.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
transaction was completed following fulfillment of certain conditions which
included, among other things, receipt of the following documents and permits:
receipt of the Share Transfer Agreement signed by the Company and Xtepo, receipt
of the Tel-Aviv Stock Exchange&#8217;s approval for registration of the securities in
accordance with the Share Transfer Agreement, and receipt of the Company&#8217;s
shareholders meeting approval to engage in the Share Transfer Agreement (which
was received on March 2, 2010).</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
addition, the Company, Bio-Gal, Ltd. (&#8220;Bio-Gal&#8221;), Xtepo and Xtepo&#8217;s shareholders
have reached an understanding with the Israeli Tax Authority regarding the
transaction as being exempt from taxation according to articles 104b(f), 103c
and 103t of the Income Tax Ordinance (New Version, 1961, the &#8220;Ordinance&#8221;). The
Israeli Tax Authority&#8217;s approval was received on June 1, 2010 and was approved
by the Company and Xtepo&#8217;s and Bio-Gal&#8217;s shareholders on July 15,
2010.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According
to the outline of the transaction, the Company acquired 100% of Xtepo&#8217;s shares,
Xtepo being a privately owned company associated in Israel on November 9, 2009,
by Bio-Gal&#8217;s shareholders. Bio-Gal received an exclusive license on a patent for
the Erythropoietin drug (&#8220;EPO&#8221;) and in its ownership are 1.5 million USD,
against the allocation of 133,063,688 new shares of the Company to Xtepo&#8217;s
shareholders in an <font style="DISPLAY: inline; TEXT-DECORATION: none">extraordinary private
placement</font> according to the Israeli Securities Authority Regulations
(Private Offering of Securities in a Registered Company, 2000) (&#8220;The
Regulations&#8221;).&#160;&#160;Following the completion of the Share Transfer
Agreement, Xtepo&#8217;s shareholders will own (including their ownership of the
Company&#8217;s shares on the eve of the share transfer) approximately 70.64% of the
Company&#8217;s issued and paid up capital and the remainder, approximately 29.36%,
will be owned by the Company&#8217;s shareholders.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 3
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company shares that will be allocated to Xtepo&#8217;s shareholders will be registered
with Bank Hapoalim Registrar Company Ltd.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
mentioned in the outline published on January 15, 2010 (ref. 2010-01-355722),
the Company intends to commence preparations for a Phase 2 clinical trial in
order to prove EPO&#8217;s advantages in the treatment of Multiple Myeloma
patients.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company&#8217;s evaluation of the development of the drug and commencement of
preparations for a Phase 2 clinical trial are forward-looking statements. This
information is uncertain and is based on the Company&#8217;s existing information as
of the date of the report. The actual outcome may be substantially different
than any possible outcome deduced from this information.&#160;&#160;There is no
certainty regarding a receipt of exemption from conducting Phase 1 clinical
trials and/or regarding the results of the experiments that the Company conducts
on the drug.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">In accordance with the
understandings reached with the Israeli Tax Authority and approved by the
Company, Xtepo, Bio-Gal and their shareholders on July 15</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super; TEXT-DECORATION: underline">th</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">, 2010, the conditions for
the asset transfer and the share transfer were determined.&#160;&#160;A summary
of the material conditions is as follows</font>:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      balance of the Company&#8217;s business losses and the balance of the Company&#8217;s
      capital losses have been reduced and set on a total of around 80 million
      NIS and around 0.7 million NIS, respectively. This is not to reduce the
      income tax assessor&#8217;s authority to determine that the balance of the
      losses is lower than the
aforementioned.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Losses
      that the Company incurred prior to the share transfer after their
      reduction as detailed in Section 1 above will not be allowed for
      compensation against any income deriving from Xtepo (the transferred
      company) and in addition will not be allowed for compensation against
      capital gains deriving from the sale of Xtepo&#8217;s
  shares.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Xtepo&#8217;s
      shareholders will not be allowed to sell their rights in the Company for
      two years commencing at the end of the year in which the transaction was
      completed (the &#8220;Block Period&#8221;). Subject to changes in
      legislation.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company and Xtepo have undertaken that during the Block Period, the
      principal economic activity in which they were engaged on the eve of the
      transaction will continue.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company will not be authorized to sell its shares in Xtepo for the
      entirety of the Block Period.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Respectfully,</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
Biopharmaceuticals, Ltd.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 4
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
Relations, XTL Biopharmaceuticals Ltd.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +972
3 612 7011, Email: ir@xtlbio.com</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cautionary
Statement</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some of
the statements included in this Form 6-K may be forward-looking statements that
involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 5
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <table border="0" cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">XTL BIOPHARMACEUTICALS
      LTD.</font></font></td>
            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td colspan="2" valign="top" width="38%">&#160;</td>
            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:
      August 4, 2010</font></div>
            </td>
            <td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:
      </font></div>
            </td>
            <td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font size="2">/s/ David Grossman</font></td>
            <td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">David
      Grossman</font></td>
            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Executive Officer</font></td>
            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 6
- -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!(`-0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BL+Q=KM
MWX:\/RZK::6=1\@@S1++Y96/G+YVMG'&>.F3VKS'_AH$_P#0L#_P8?\`VNM(
M4IS5XHSG5A!VDSTCQEXRT_P9I/VR\!EFD)2WMT8!I7`S^"CC+=LC@D@'A-(^
M.]E=ZC'!J6CR65NY"F=+@2A"2!DC:O'<D9/'0USWQ-U5O&OA/0?$UA!(+6$S
M0WD>Y6^RRDI@-CG!QP3Q@KP"V#YC8V-UJ5[#964+S7$S;8XT')/^>]=M'#0<
M+SW_`".6KB)J?N['V;17DNK_`!1C\!/9>&4T]=5FL+*&*XG%R8@)`H!&"C9X
MP<Y_BQU!J3PW\8[OQ-K]II5KX7(:=P'D%]GRD_B<CRQT&3C//3J:X_8SM>VA
MT^VA?EOJ>K45Y=XM^,)\+>)[S1O[!^U?9MG[[[9LW;D5NFPX^]CKVK%_X:!/
M_0L#_P`&'_VNA4*C5TA.O33LV>UT5XI_PT"?^A8'_@P_^UT?\-`G_H6!_P"#
M#_[73^KU>P?6*7<]KHKQ3_AH$_\`0L#_`,&'_P!KH_X:!/\`T+`_\&'_`-KH
M^KU>P?6*7<]KHKSSP'\4?^$VUN?33HYLC';F<2"Y\P'#*N,;5Q]ZO0ZSE!Q=
MI&D9J2O$***S=>U;^Q-&N-1\GSA#M^3=MSE@O7!]:23DTEU"<U"+E+9&E17-
M^$_%9\3B[W6(M3;[.DWF;MV[_9&/NUTE5.$H2Y9+4FE5A5@IP=TPHHHJ#0**
MY#Q1XW;PYJ<=FNFBYW1"3>9]F,DC&-I]*Z;3[O[?IMK>;-GGPI+LSG;N`.,_
MC6DJ4XQ4VM&8PQ%*I-TXO5;EFBBBLS8****`"BBB@".X@ANK>2WN(DEAE4I)
M&ZY5E/!!!Z@U\L_$#PA+X0\2RVRH_P!@G)ELY"#@IW7.3DKG!YST/&17U57)
M?$3PA'XO\,2P)&IU"W!ELWP,[^Z9)&`V,'G&<'G%=&'J^SGKLS"O2]I'3='C
M/PC\3#2/$XTF[.[3M5Q`\;#*B4\(<8/4G:>@^8$]*]B\2S:#\/O#UYK5CI6G
MVEX4,,'DVR(9';[JG&"5R,D9Z*3VKY<=&C=D=2KJ<,K#!!]#71^*O&FH^+8=
M-COMH^Q0["5_Y:N>LAXX)`7CIP2,9Q795P_/-26W4Y*=?E@X]>AS]Q/+=7,M
MQ<2-+-*Y>21SDLQ.22?4FOHSX3>"/^$:T0ZE?1%=4OE!973#01]0G/()X+=.
M<#'RYKS/X3>"AXEUTZC?0A]+L&!=9$)6:3'RIZ$#AB.>P(PU?2-98NK_`,NU
M\S7"TOML\:\<?";7_$OC&_U>SNM.CM[CR]BS2N'&V-5.0$(ZJ>]<]_PHGQ1_
MS^Z1_P!_I/\`XW7T-16$<54BDD;/#0;NSXTU*PETO5;S3IV1IK6=X'*$E2RL
M5.,XXR*WO"'@/5/&HO#IL]G%]DV>9]H=ESNW8QM4_P!TU2\8_P#(\:__`-A*
MX_\`1C5ZA^S]_P`S%_V[?^U:]"K4<:7,MSAIP4JG*S#_`.%$^*/^?W2/^_TG
M_P`;K@_$.A77AK7;G2+UX7N+?;O:$DJ=RAA@D`]&':OL*OE_XM_\E/UC_MC_
M`.B8ZPPU>=2=I&V(HQA&\3:^!/\`R/%Y_P!@Z3_T9'7T-7SS\"?^1XO/^P=)
M_P"C(Z^AJY\7_%-\+_#"N;\>_P#(F7_TC_\`1B5TE<WX]_Y$R_\`I'_Z,2HP
M_P#&AZK\Q8S_`':I_A?Y'._"G[NK?6'_`-GKT:O&/"WB:/PWI^IL$\RZF\H0
MH>G&[)/L,CZY_$,DOO&&I,MVC:NR2#Y3;HZQXSV"@#OU_P`*]'%8256M*;:2
MTW]$>+@<QA0PL*<8N4M=%TU9[517BUGXJ\1:%>[+J6YDPV9(+P$L>/5OF7\/
MUKU?0M:@U[2H[Z`;-W#QE@2C#J#C\_H0:X:^%G15WJNYZF$S"EB6XJZDNC,[
M7?!EAX@OUO+F>YCD6,1@1%0,`D]P?6MRRM$L;&WM(V9D@C6)2W4A1@9K@/'7
MB35M'UV.WL+OR86MU<KY:-\VYAGD'T%=QHL\MUH=A<3-OEEMHW=L8RQ4$G]:
M=6-54H.3O'H+#U,/+$5(TXVDMWW_`!+U%<%XM\>/I]P^GZ5L:X0D33,-PC..
MB\\L#USP,8P>W,6Y\:ZR&NH)=39&&[<LIB0C_9&0#^%73P4Y1YY-17F9ULUI
MPJ.G3BYM=CV2BO&+;Q3XG\/W*I=27+9^;R;Y6.X=,Y/S8^AQ7J'A[Q!:^(K#
M[1;Y1TP)8FZHW]1Z'^N145\).DN;==T:X3,*6);@KJ2Z,UZ***Y3O"BBL?Q1
MXBL_"V@7.J7;H/+4^5$S;3-)CY4'!Y/T.!D]`::3;LA-I*[/"/C/I&G:;XR$
M]E,HFO8_/N+=4P(VZ;L@8^;!)')R"3]X5YS5W5]4NM;U>ZU.]?=<7,AD?DD#
M/0#))``P`.P`%&HZ3?:4+0WL'E?:[=+J#YE;?&V=K<$XSCH>:]JG%QBHMZGD
M3?-)R2/J/P!:Z7:>!]*&D$-;20+(9,`,\A'SE@"<-NR",G&,=JZ6OGWX,^,A
MI.K'P]>-BTOY-T#'`$<^,8)ZX8`#OR%P.2:^@J\FO!PFTSTZ,U."L%%%%9&I
M\B^,?^1XU_\`["5Q_P"C&KU#]G[_`)F+_MV_]JUY?XQ_Y'C7_P#L)7'_`*,:
MO4/V?O\`F8O^W;_VK7JU_P"!]QYM'^-]Y[57R_\`%O\`Y*?K'_;'_P!$QU]0
M5\O_`!;_`.2GZQ_VQ_\`1,=<N"_B/T.C%_`O4VO@3_R/%Y_V#I/_`$9'7T-7
MSS\"?^1XO/\`L'2?^C(Z^AJG%_Q2L+_#"N;\>_\`(F7_`-(__1B5TE<WX]_Y
M$R_^D?\`Z,2HP_\`&AZK\Q8S_=JG^%_D>=>!=*M]6\2I'=`/%!&9S&PR'P0`
M#[98'\,=Z]IKS;X5*#)JK8&X"(`_]]UZ371F$W*LUV.+):48X526\K_G8YOQ
MMH]OJGAZYED1?.M8VGBD(Y7:,D#Z@8__`%5P_P`-M0-MXADLR3LNXB,8'WD^
M8$GZ;_SKUB?8()/,V[-IW;NF,<YKQCP'_P`CII^/^FG_`*+:M,*^?#5(/9?U
M^ASY@O9XZC4CNW9_>E^3-#XF?\C-#_UZK_Z&]=C-J4FD?#BWO8<>:EC"J$]F
M954'\,YKCOB9_P`C-#_UZK_Z&]:WBO=_PK31=N[&VW#8]/*[^V<?I6CBITZ,
M7W,8U'3KXJ<=TCG_``)H*:UK9DN(U>TM1OD5AD.QX53SZY/<?+CO7LM><_"K
M[NK=.L/U_CKT:N;,)N5=I]#OR:E&&%4EN]_O,?Q)H-OK^E/;2*!.H+02="C_
M`.!Z$?UQ7F'@74WTOQ1##(Q2*Y/D2*V?O?P\>N[`R>@)KV>O$AC_`(6+QT_M
M;_VM6V"DYTYTY;6.?-8JG7I5XZ2O;U/;:***\P]T.E?-?Q7\:_\`"3:_]ALI
M]VE6)VH4?<DTG>3C@CG`Z\9(^\:]>^)VJ:U8^&_LF@:??W-[>DQF6T@:3R$&
M-Q.`<$YP/J2#D5\]_P#"'>*/^A;UC_P!E_\`B:[L)"*]^7R./%3=N1&K\-_"
M'_"7^)TAN$8Z=;`379&X!AGA,CH6/N#@,1R*]M^*'A$>)_"CM;QDZA8!IK8*
M"2PXW(``2<@<`?Q!?>KGP[\)IX3\*P6\D06_G`EO&QSO/\.<D84?+P<'!/>N
MLK*MB&ZG-'IL:4J*5/EEU/BJOI_X9>-#XO\`#O\`I3?\3.SQ'=?+M#YSM<8]
M0.>G(;@#&?+OB=\/]4MO%TUYHVE7EW97P\\FV@:3RY2?G4XR1D_-R`/FP/NF
MLKP;:>+_``EXDM]3B\-ZP8O]7<(-/D8O$2-P&0.>,CGJ!GC-==50K4[K?H<U
M-RHSLUH?3E%(K!E##.",\C!_*EKRST3Y%\8_\CQK_P#V$KC_`-&-7J'[/W_,
MQ?\`;M_[5KAO%?A3Q'<^,-;G@T#5989;^=TD2SD964R,000,$$=Z]&^!^C:I
MI(UTZEIUY9>;]G\O[3`T>['F9QN`SC(_.O3KRC["U^QYU&+]M>W<]=KY?^+?
M_)3]8_[8_P#HF.OJ"OG/XG^&]>U#XBZK=66B:E<V[^3MEAM7=&Q"@."!@\@C
M\*YL&TJCOV.C%)N"MW,SX7>)].\)^)KB_P!4:18)+-H5,:;CN+H1Q]%->M_\
M+J\(?\];S_P'->$_\(=XH_Z%O6/_``!E_P#B:/\`A#O%'_0MZQ_X`R__`!-=
M<Z5*<N9LY85:D%9(]V_X75X0_P">MY_X#FLWQ!\3O#GB+1+C2["2Y-S/MV!X
M2HX8,>?HIKQO_A#O%'_0MZQ_X`R__$UH:)X1\2QZQ`\GA[544;LL]G(`/E/<
MBG3H48S4K[/N9XFM6E1G&VZ?3R/3?AUJZ:?KCVDS!8[Q0H)Q]\<J,Y[Y(^I%
M>NUXOIG@K4M0L+]VMKF"[@"-#%+'L64'=D`D#G@=\>N,YIS:_P",-%C6">>\
MA`+!3<0ABW/.&8'/7U].U/$8>.(J.5.2OU.+!8RI@J*C7@^7HU^3/0_&NK6^
MG>&[J.1QYUS&T,:!L$[A@D?0'/\`^NN+^&FF&XUJ:_>/,=M&51\]';C_`-!W
M?G5"WT'Q)XJU%)[U+C:Q`:XN%VA4/]T'&1UX']:]4T/1K?0M-CLK;Y@O+.0`
M78]2<?E]`*SJ..&H.DG>3W-Z,:F.Q4<1*+C".U^IYM\3/^1FA_Z]5_\`0WKL
M+G3I-5^&T%I%GS6L(60`?>*JK`?CC'XUS?Q!TC4K_P`0Q2VEA<SQBV52T43,
M`=S<9`]Z[_0HY(?#^G12HR2):Q*RL,$$(`014UJBC0I.+U0\/0<\774UI)6/
M*_`>MPZ/K;1W+[+>["QLQ'`<'Y23V'+#TYR>!FO9*\Z\6>`9[F[FU'22'>5M
MTELQ`.XGDJ3^>#[\]!7-0:YXKT.-+027<"G_`%<<\&X^F%W`G'3@<5I5HPQ;
M]I2>O5,RP^)J9<G0KQ;BMFCU;7]9M]#TB:\F92P!$49;'F/CA1_^HX&3VKRC
MP;82ZOXNMI)-[K"YN9I-W.5.03GKEL9[\TXZ7XI\47L;74-V^>1)<*4C0'`)
M&0`.QPO6O4?#WAVS\.V7DVXWROCSIB/FD(S^0&3@=OKDTFX86E**=Y2_`I*I
MF.(C4<>6G'OU-BBBBO+/?"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
=HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
